Posted by Michael Wonder on 20 Mar 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis
17 March 2022 - Approval supported by data from two Phase 3 studies evaluating Skyrizi in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2.
AbbVie announced Health Canada has approved Skyrizi (risankizumab), for the treatment of adult patients with active psoriatic arthritis. In psoriatic arthritis, Skyrizi can be used alone or in combination with a conventional non-biologic disease-modifying anti-rheumatic drug (e.g., methotrexate).
